Literature DB >> 23387413

Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-bioartificial liver.

Geert A A Nibourg1, Ruurdtje Hoekstra, Tessa V van der Hoeven, Mariëtte T Ackermans, Theodorus B M Hakvoort, Thomas M van Gulik, Robert A F M Chamuleau.   

Abstract

BACKGROUND & AIMS: The AMC-bioartificial liver loaded with the human hepatoma cell line HepaRG as biocomponent (HepaRG-AMC-BAL) has recently proven efficacious in rats with acute liver failure (ALF). However, its efficacy may be affected by cytotoxic components of ALF plasma during treatment. In this study, we investigated the effects of ALF-plasma on the HepaRG-AMC-BAL.
METHODS: HepaRG-AMC-BALs were connected to the blood circulation of rats with total liver ischaemia, either during the first 5 h after induction of ischaemia (mild ALF group), or during the following 10 h (severe ALF group). After disconnection, the BALs were assessed for cell leakage, gene transcript levels, ammonia elimination, urea production, cytochrome P450 3A4 activity, apolipoprotein A 1 production, glucose and amino acid metabolism.
RESULTS: Cell leakage increased 2.5-fold in the severe ALF group, but remained limited in all groups. Hepatic gene transcript levels decreased (max 40-fold) or remained stable. In contrast, hepatic functions increased slightly or remained stable. Particularly, urea production increased 1.5-fold, with a concurrent increase in arginase 2 transcription and arginine consumption, with a trend towards reduced conversion of ammonia into urea. The amino acid consumption increased, however, the net glucose consumption remained stable.
CONCLUSIONS: The HepaRG-AMC-BAL retains functionality after both mild and severe exposure to ALF plasma, but urea production may be increasingly derived from arginase 2 activity instead of urea cycle activity. Nevertheless, the increase in cell leakage and decrease in various hepatic transcript levels suggest that a decrease in hepatic functionality may follow upon extended exposure to ALF plasma.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23387413     DOI: 10.1111/liv.12090

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Assessment of liver function: what are we measuring?

Authors:  Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2013-05       Impact factor: 3.647

2.  Integration of single-layer skin hollow fibers and scaffolds develops a three-dimensional hybrid bioreactor for bioartificial livers.

Authors:  Shichang Zhang; Li Chen; Tao Liu; Zhengguo Wang; Yingjie Wang
Journal:  J Mater Sci Mater Med       Date:  2013-08-21       Impact factor: 3.896

3.  Alleviating liver failure conditions using an integrated hybrid cryogel based cellular bioreactor as a bioartificial liver support.

Authors:  Apeksha Damania; Mohsin Hassan; Nana Shirakigawa; Hiroshi Mizumoto; Anupam Kumar; Shiv K Sarin; Hiroyuki Ijima; Masamichi Kamihira; Ashok Kumar
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

Review 4.  Stem Cell Therapies for Treatment of Liver Disease.

Authors:  Clara Nicolas; Yujia Wang; Jennifer Luebke-Wheeler; Scott L Nyberg
Journal:  Biomedicines       Date:  2016-01-06

5.  A New Fluidized Bed Bioreactor Based on Diversion-Type Microcapsule Suspension for Bioartificial Liver Systems.

Authors:  Juan Lu; Xiaoqian Zhang; Jianzhou Li; Liang Yu; Ermei Chen; Danhua Zhu; Yimin Zhang; LanJuan Li
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.